文献速递心脑血管急症重症综合管理与镇静镇痛

养老院房颤合并ADL障碍患者的抗凝结局

Anticoagulation Outcomes in Nursing Home Residents With Atrial Fibrillation and ADL Disability.
PubMed 文献 · JAMA Netw Open · 2026-10-01
一句话结论在养老院房颤合并ADL障碍居民中,口服抗凝药与缺血性卒中减少相关但大出血增加,其中阿哌沙班的获益-风险特征最有利。

这项基于美国Medicare理赔与Minimum Data Set链接的队列研究(2013年1月1日至2022年12月31日)纳入26940例非瓣膜性房颤且3项及以上ADL受损的养老院居民,通过倾向性评分匹配比较阿哌沙班、利伐沙班或华法林启动与未使用者的结局。与未使用相比,三种口服抗凝药均与缺血性卒中发生率降低相关(阿哌沙班ARR 0.53,95%CI 0.38-0.73;利伐沙班ARR 0.48,95%CI 0.27-0.87;华法林ARR 0.47,95%CI 0.25-0.88),但均与大出血发生率升高相关。仅阿哌沙班与复合结局升高无显著相关(ARR 1.08,95%CI 0.90-1.30),利伐沙班(ARR 1.62)和华法林(ARR 1.99)则与复合结局升高相关。作者认为这些发现可能有助于个体化抗凝决策。

要点

  • 在养老院房颤合并3项及以上ADL障碍居民中,阿哌沙班与缺血性卒中减少相关(ARR 0.53,95%CI 0.38-0.73)但大出血增加(ARR 1.62,95%CI 1.29-2.03)。
  • 仅阿哌沙班与复合结局升高无显著相关(ARR 1.08,95%CI 0.90-1.30),利伐沙班(ARR 1.62,95%CI 1.20-2.18)和华法林(ARR 1.99,95%CI 1.50-2.63)与复合结局升高相关。
  • 利伐沙班大出血ARR 2.68(95%CI 1.84-3.93),华法林大出血ARR 3.02(95%CI 2.15-4.25),均高于阿哌沙班。
  • tipping-point分析提示阿哌沙班较利伐沙班或华法林具有更有利的获益-风险平衡。
  • 在衰弱分层中结果一致,但阿哌沙班的卒中减少在衰弱个体中减弱。

适用人群与场景

  • 长期养老院居民,非瓣膜性房颤且3项及以上日常生活活动(ADL)受损,来自美国Medicare理赔与Minimum Data Set链接数据(2013年1月1日至2022年12月31日)。

研究设计与关键结果

  • 研究类型为队列研究,共纳入26940例养老院居民(中位[IQR]年龄82[74,88]岁;17504例[65.0%]女性),倾向性评分匹配后阿哌沙班组7600例、利伐沙班组2654例、华法林组3216例,倾向性评分匹配平衡了111个协变量。
  • 与未使用相比,阿哌沙班与缺血性卒中发生率降低相关(ARR 0.53,95%CI 0.38-0.73),利伐沙班ARR 0.48(95%CI 0.27-0.87),华法林ARR 0.47(95%CI 0.25-0.88)。
  • 与未使用相比,阿哌沙班与大出血发生率升高相关(ARR 1.62,95%CI 1.29-2.03),利伐沙班ARR 2.68(95%CI 1.84-3.93),华法林ARR 3.02(95%CI 2.15-4.25)。
  • 仅阿哌沙班与复合结局升高无显著相关(ARR 1.08,95%CI 0.90-1.30),利伐沙班(ARR 1.62,95%CI 1.20-2.18)和华法林(ARR 1.99,95%CI 1.50-2.63)与复合结局升高相关。
  • 在衰弱分层中结果一致,但阿哌沙班的卒中减少在衰弱个体中减弱。
  • tipping-point分析提示阿哌沙班较利伐沙班或华法林具有更有利的获益-风险平衡。

证据类型、等级与局限

  • 证据类型为基于美国Medicare理赔与Minimum Data Set链接的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在养老院房颤合并ADL障碍居民中,使用口服抗凝药与缺血性卒中减少相关,但大出血增加,临床决策需个体化权衡。
  • 阿哌沙班在评估的口服抗凝药中显示出最有利的获益-风险特征。
  • 作者认为这些发现可能有助于个体化抗凝决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Long-term nursing home residents with atrial fibrillation (AF) and activities of daily living (ADL) disability are at high risk of bleeding and death, making the net benefit of anticoagulation uncertain.

OBJECTIVE: To compare the association of oral anticoagulant (OAC) use vs nonuse with ischemic stroke and major bleeding in long-term nursing home residents with AF and ADL disability.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used US Medicare claims linked with the Minimum Data Set (January 1, 2013, to December 31, 2022). Nursing home residents with nonvalvular AF and impairment in 3 or more ADLs were included. Three cohorts comparing use of apixaban, rivaroxaban, or warfarin with nonuse were constructed using incidence-density sampling.

EXPOSURES: Initiation of apixaban, rivaroxaban, or warfarin use.

MAIN OUTCOMES AND MEASURES: Primary outcomes were ischemic stroke, major bleeding, and their composite. Propensity score (PS) matching balanced 111 covariates. Adjusted rate ratios (ARRs) with 95% CIs were estimated. Tipping-point analyses assessed the relative weighting ischemic stroke vs major bleeding required to favor anticoagulation. Direct active-comparator analyses compared apixaban with rivaroxaban and warfarin.

RESULTS: The study comprised 26 940 nursing home residents (median [IQR] age, 82 [74,88] years; 17 504 [65.0%] female), including PS-matched cohorts of 7600 residents receiving apixaban, 2654 receiving rivaroxaban, and 3216 receiving warfarin. Compared with nonuse, use of all OACs was associated with lower rates of ischemic stroke (apixaban: ARR, 0.53; 95% CI, 0.38-0.73; rivaroxaban: ARR, 0.48; 95% CI, 0.27-0.87; warfarin: ARR, 0.47; 95% CI, 0.25-0.88) and higher rates of major bleeding (apixaban: ARR, 1.62; 95% CI, 1.29-2.03; rivaroxaban: ARR, 2.68; 95% CI, 1.84-3.93; warfarin: ARR, 3.02; 95% CI, 2.15-4.25). Only apixaban was not associated with a higher composite outcome (ARR, 1.08; 95% CI, 0.90-1.30), whereas rivaroxaban (ARR, 1.62; 95% CI, 1.20-2.18) and warfarin (ARR, 1.99; 95% CI, 1.50-2.63) were associated with higher rates. Findings were consistent across frailty strata, although stroke reduction with apixaban was attenuated among frail individuals. Tipping-point analyses indicated a more favorable benefit-risk balance for apixaban than for rivaroxaban or warfarin.

CONCLUSIONS AND RELEVANCE: Among nursing home residents with AF and ADL disability, OAC use was associated with lower ischemic stroke but higher major bleeding rates than nonuse. Apixaban demonstrated the most favorable benefit-risk profile among the OACs evaluated. These findings may inform individualized anticoagulation decisions.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chen Q, Singer D, Yang CT, et al. Anticoagulation Outcomes in Nursing Home Residents With Atrial Fibrillation and ADL Disability. JAMA Netw Open. 2026. PMID: 42832198. doi:10.1001/jamanetworkopen.2026.37533

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。